XKRX:000520 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XKRX:000520 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Samil Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Jun. 2024 was ₩. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₩0.00 for the trailing ten years ended in Jun. 2024.
During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -19.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Samil Pharmaceutical Co was 11.40% per year. The lowest was -19.90% per year. And the median was -1.90% per year.
As of today (2024-10-31), Samil Pharmaceutical Co's current stock price is ₩16000.00. Samil Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 was ₩0.00. Samil Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for Samil Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samil Pharmaceutical Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | -800.13 | -746.02 | -884.21 | -1,253.92 | -1,286.84 |
Samil Pharmaceutical Co Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | -1,273.60 | -1,355.30 | -1,286.84 | -1,293.27 | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Samil Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Samil Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Samil Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Samil Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Jun. 2024 (Change) | * | Current CPI (Jun. 2024) |
= | 36.94 | / | * | |||
= |
Current CPI (Jun. 2024) = .
Samil Pharmaceutical Co Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201409 | -513.990 | 99.608 | 0.000 |
201412 | -160.332 | 99.098 | 0.000 |
201503 | -4.282 | 99.720 | 0.000 |
201506 | 21.982 | 100.050 | 0.000 |
201509 | -188.321 | 100.110 | 0.000 |
201512 | 200.496 | 100.220 | 0.000 |
201603 | -134.098 | 100.560 | 0.000 |
201606 | 302.911 | 100.790 | 0.000 |
201609 | 136.894 | 101.460 | 0.000 |
201612 | -207.151 | 101.560 | 0.000 |
201703 | -185.633 | 102.850 | 0.000 |
201706 | -3,306.510 | 102.610 | 0.000 |
201709 | -142.663 | 103.490 | 0.000 |
201712 | 218.535 | 102.990 | 0.000 |
201803 | -214.760 | 104.100 | 0.000 |
201806 | -113.587 | 104.130 | 0.000 |
201809 | -124.324 | 105.650 | 0.000 |
201812 | -100.370 | 104.350 | 0.000 |
201903 | -248.286 | 104.490 | 0.000 |
201906 | 443.625 | 104.880 | 0.000 |
201909 | -1,095.374 | 105.200 | 0.000 |
201912 | 618.392 | 105.120 | 0.000 |
202003 | 224.982 | 105.540 | 0.000 |
202006 | -235.464 | 104.870 | 0.000 |
202009 | -185.464 | 106.200 | 0.000 |
202012 | -282.974 | 105.765 | 0.000 |
202103 | -277.232 | 107.357 | 0.000 |
202106 | -450.836 | 107.579 | 0.000 |
202109 | -554.129 | 108.759 | 0.000 |
202112 | -724.394 | 109.676 | 0.000 |
202203 | -826.874 | 111.806 | 0.000 |
202206 | -748.429 | 114.083 | 0.000 |
202209 | -1,296.285 | 114.831 | 0.000 |
202212 | -42.197 | 115.200 | 0.000 |
202303 | -33.039 | 116.550 | 0.000 |
202306 | -315.031 | 117.140 | 0.000 |
202309 | -540.950 | 119.111 | 0.000 |
202312 | 358.264 | 118.848 | 0.000 |
202403 | -186.272 | 118.848 | 0.000 |
202406 | 36.940 | 0.000 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Samil Pharmaceutical Co (XKRX:000520) Cyclically Adjusted FCF per Share Explanation
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Be Aware
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Samil Pharmaceutical Co's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.